Avraham D, Herman A, Shaham G, Shklyar A, Sulim E, Oulianski M. Lab results of COVID-19 patients: Omicron vs delta variants. World J Virol 2024; 13(2): 90761 [PMID: 38984078 DOI: 10.5501/wjv.v13.i2.90761]
Corresponding Author of This Article
Dana Avraham, MD, Doctor, Orthopedic Department, Kaplan Medical Center, Pasternak 1, Rehovot 7661041, Israel. danaav7111@gmail.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Virol. Jun 25, 2024; 13(2): 90761 Published online Jun 25, 2024. doi: 10.5501/wjv.v13.i2.90761
Lab results of COVID-19 patients: Omicron vs delta variants
Dana Avraham, Amir Herman, Gal Shaham, Arkady Shklyar, Elina Sulim, Maria Oulianski
Dana Avraham, Amir Herman, Maria Oulianski, Orthopedic Department, Kaplan Medical Center, Rehovot 7661041, Israel
Gal Shaham, Department of Medicine, Lithuanian University of Health Sciences, Kaunas 44307, Lithuania
Arkady Shklyar, Elina Sulim, Emergency Department, Kaplan Medical Center, Rehovot 7661041, Israel
Author contributions: Avraham D and Oulianski M designed the research; Herman A and Shaham G performed the research; Shklyar A contributed new reagents/analytic tools; Oulianski M and Sulim A analyzed the data; Avraham D and Oulianski M wrote the paper.
Institutional review board statement: The study was reviewed and approved by the "Kaplan Medical Center" Helsinki Committee Institutional Review Board [(Approval No. 0018-22-KMC]).
Informed consent statement: According to the Helsinki Committee decision, our study does not require inform consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The authors commit to making the data and materials underlying the findings of this medical article available upon reasonable request. Requests for data should be directed to [Dr. Dana Avraham at Danaav7111@gmail.com. The authors aim to facilitate transparency and reproducibility in scientific research and encourage collaboration within the scientific community. Access to the data will be provided in compliance with ethical standards and institutional regulations.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dana Avraham, MD, Doctor, Orthopedic Department, Kaplan Medical Center, Pasternak 1, Rehovot 7661041, Israel. danaav7111@gmail.com
Received: December 12, 2023 Revised: January 26, 2024 Accepted: March 6, 2024 Published online: June 25, 2024 Processing time: 194 Days and 13.3 Hours
ARTICLE HIGHLIGHTS
Research background
The article provides a comprehensive overview of the timeline and global impact of the coronavirus disease 2019 (COVID-19) pandemic, emphasizing the emergence of variants such as delta and omicron. Noteworthy symptoms of COVID-19 and the heightened risk among the elderly population are highlighted, including severe acute respiratory distress syndrome risks. The delta variant, identified in India in late 2020, is characterized by increased transmissibility and a higher risk of hospitalization. The omicron variant, first detected in Botswana and South Africa in early 2022, raised concerns due to a significant number of spike protein mutations.
Research motivation
To shed light on the laboratory aspects of COVID-19 patients during the emergence of the delta and omicron variants.
Research objectives
To providing valuable insights into the initial testing phase within the emergency department setting.
Research methods
The study included 100 adult patients, 50 for each variant, with comprehensive laboratory assessments. Rigorous exclusion criteria were applied to ensure the focus on COVID-19-related factors.
Research results
No statistically significant differences were identified in age, gender, and comorbidities between delta and omicron groups. Laboratory analyses, including complete blood count, coagulation, and blood chemistry, revealed no significant variations between the two variants.
Research conclusions
COVID-19 continues to mutate and evolve with different variants emerging, Future research endeavors should consider encompassing diverse variants to ensure a more nuanced and systemic approach to addressing the challenges posed by COVID-19.
Research perspectives
Both omicron and delta variants show high infection rates, similar laboratory results, but clinical evaluation should be conducted to determine the true similarity of those variants.
